Advertisement

Mental Health and Substance Use in the Scale-Up of HIV Prevention

  • Aaron J. BlashillEmail author
  • Jonathan Lassiter
  • Johannes M. Wilson
  • Steven A. Safren
  • Jeffrey T. Parsons
Chapter

Abstract

The past several years have witnessed dramatic advances in the potential for effective biomedical HIV prevention interventions. Recent landmark clinical trials, such as CAPRISA 004 and iPrEx, have shown that vaginal microbicides and oral preexposure prophylaxis (PrEP) can reduce the likelihood of HIV infection. Additionally, the results of HIV Prevention Trials Network (HPTN) 052 showed that early initiation of antiretroviral therapy (ART) could also function as a potential biomedical HIV prevention intervention. Nonetheless, many other trials of microbicides and PrEP failed to show a decrease in HIV incidence. Across these trials, it has been hypothesized that poor levels of treatment adherence accounted for the ineffectiveness of the interventions. It is well known that numerous mental health and substance use issues impact adherence to ART, and it is likely that adherence to PrEP and microbicides is similarly affected by these intertwined psychosocial problems. In this chapter, we discuss the impact of mental health and substance use on adherence, HIV transmission risk behavior, PrEP, microbicides, and ART as a secondary prevention strategy. Specifically, we examine how psychosocial syndemics, stigma, risk compensation, intimate partner violence, and the use of various substances (such as alcohol, cocaine, club drugs, methamphetamines) have been important factors in HIV treatment and prevention research to date, and then we present current research that applies these findings to biomedical prevention efforts. Finally, we discuss future research directions for addressing mental health and substance use issues in biomedical prevention interventions.

Keywords

Intimate Partner Violence Childhood Sexual Abuse Sexual Risk Behavior Microbicide Trial PrEP Adherence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Padian NS, Buvé A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372(9638):585–99.PubMedGoogle Scholar
  2. 2.
    Celum CL. HIV preexposure prophylaxis: new data and potential use. Top Antivir Med. 2011;19(5):181–5.PubMedGoogle Scholar
  3. 3.
    Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedGoogle Scholar
  4. 4.
    MacQueen KM. Framing the social in biomedical HIV prevention trials: a 20-year retrospective. J Int AIDS Soc. 2011;14(Suppl 2):S3.PubMedGoogle Scholar
  5. 5.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.PubMedGoogle Scholar
  6. 6.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedGoogle Scholar
  7. 7.
    Rudy BJ, Kapogiannis BG, Lally MA, et al. Youth-specific considerations in the development of PrEP, microbicide and vaccine research trials. J Acquir Immune Defic Syndr. 2010;54(Suppl 1):S31–S42.PubMedGoogle Scholar
  8. 8.
    Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003) [Internet]. Presented at the 20th Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3–6; Atlanta, GA. http://www.retroconference.org/2013b/Abstracts/47951.htm.
  9. 9.
    Omar RF, Bergeron MG. The future of microbicides. Int J Infect Dis. 2011;15(10):e656–60.PubMedGoogle Scholar
  10. 10.
    Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.PubMedGoogle Scholar
  11. 11.
    Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedGoogle Scholar
  12. 12.
    Van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–9.PubMedGoogle Scholar
  13. 13.
    Cochran SD, Mays VM. Relation between psychiatric syndromes and behaviorally defined sexual orientation in a sample of the US population. Am J Epidemiol. 2000;151(5):516–23.PubMedGoogle Scholar
  14. 14.
    Cochran SD, Mays VM, Sullivan JG. Prevalence of mental disorders, psychological distress, and mental health services use among lesbian, gay, and bisexual adults in the United States. J Consult Clin Psychol. 2003;71(1):53–61.PubMedGoogle Scholar
  15. 15.
    Sandfort TG, De Graaf R, Bijl RV, Schnabel P. Same-sex sexual behavior and psychiatric disorders: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Arch Gen Psychiatry. 2001;58(1):85–91.PubMedGoogle Scholar
  16. 16.
    Applebaum A, Bullis JR, Traeger L, et al. Rates of mood and anxiety disorders and contributors to continued heroin use in methadone maintenance patients: a comparison by HIV status. Neurobehav HIV Med. 2010;2:49–57.Google Scholar
  17. 17.
    Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.PubMedGoogle Scholar
  18. 18.
    Pence BW, O’Donnell JK, Gaynes BN. Falling through the cracks. AIDS. 2012;26(5):656–8.PubMedGoogle Scholar
  19. 19.
    Stall R, Mills TC, Williamson J, et al. Association of co-occurring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Health. 2003;93(6):939–42.PubMedGoogle Scholar
  20. 20.
    Mustanski B, Garofalo R, Herrick A, Donenberg G. Psychosocial health problems increase risk for HIV among urban young men who have sex with men: preliminary evidence of a syndemic in need of attention. Ann Behav Med. 2007;34(1):37–45.PubMedGoogle Scholar
  21. 21.
    O’Cleirigh CM, Mimiaga MJ, Safren SA, Stall R, Mayer KH. Synergistic effects of psychosocial and substance use problems on increased sexual transmission risk among HIV-infected men who have sex with men [Internet]. Presented at the XVIII International AIDS Conference; 2010 Jul 18–23; Vienna, Austria. http://www.aids2010.org/WebContent/File/AIDS2010_Abstracts_Vol_2_Wednesday_21July_web.pdf.
  22. 22.
    Mimiaga MJ, Biello KB, O’Cleirigh CM, et al. High prevalence of syndemic conditions associated with suboptimal ART adherence in a large multinational on-line sample of HIV-infected MSM. Presentation submitted to the 141st Annual Meeting and Exposition of the American Public Health Association; 2013 Nov 2–6; Boston, MA.Google Scholar
  23. 23.
    Sikkema KJ, Watt MH, Drabkin AS, Meade CS, Hansen NB, Pence BW. Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. AIDS Behav. 2010;14(2):252–62.PubMedGoogle Scholar
  24. 24.
    Mimiaga MJ, Noonan E, Donnell D, et al. Childhood sexual abuse is highly associated with HIV risk-taking behavior and infection among MSM in the EXPLORE study. J Acquir Immune Defic Syndr. 2009;51(3):340–8.PubMedGoogle Scholar
  25. 25.
    Safren SA, Blashill AJ, O’Cleirigh CM. Promoting the sexual health of MSM in the context of comorbid mental health problems. AIDS Behav. 2011;15(1):30–4.Google Scholar
  26. 26.
    Browne FA, Wechsberg WM. The intersecting risks of substance use and HIV risk among substance-using South African men and women. Curr Opin Psychiatry. 2010;23(3):205–9.PubMedGoogle Scholar
  27. 27.
    Colfax G, Guzman R. Club drugs and HIV infection: a review. Clin Infect Dis. 2006;42(10):1463–9.PubMedGoogle Scholar
  28. 28.
    Drumright LN, Patterson TL, Strathdee SA. Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse. 2006;41(10–12):1551–601.PubMedGoogle Scholar
  29. 29.
    El-Bassel N, Gilbert L, Witte S, Wu E, Chang M. Intimate partner violence and HIV among drug-involved women: contexts linking these two epidemics–challenges and implications for prevention and treatment. Subst Use Misuse. 2011;46(2–3):295–306.PubMedGoogle Scholar
  30. 30.
    Ferrando SJ, Batki SL. Substance abuse and HIV infection. New Dir Ment Health Serv. 2000;87:57–67.PubMedGoogle Scholar
  31. 31.
    Grov C, Parsons JT, Bimbi DS. In the shadows of a prevention campaign: sexual risk behavior in the absence of crystal methamphetamine. AIDS Educ Prev. 2008;20(1):42–55.PubMedGoogle Scholar
  32. 32.
    Parsons JT, Lelutiu-Weinberger C, Botsko M, Golub SA. Predictors of day-level sexual risk for young gay and bisexual men. AIDS Behav. 2012:1–13 (Epub 2012).Google Scholar
  33. 33.
    Purohit V, Rapaka RS, Shurtleff D. Mother-to-child transmission (MTCT) of HIV and drugs of abuse in post-highly active antiretroviral therapy (HAART) era. J Neuroimmune Pharm. 2010;5(4):507–15.Google Scholar
  34. 34.
    Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.PubMedGoogle Scholar
  35. 35.
    Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011;88(21–22):940–7.PubMedGoogle Scholar
  36. 36.
    Norman LR, Basso M, Kumar A, Malow R. Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research. Curr Drug Abuse Rev. 2009;2(2):143–56.PubMedGoogle Scholar
  37. 37.
    Parsons JT, Rosof E, Mustanski B. Medication adherence mediates the relationship between adherence self-efficacy and biological assessments of HIV health among those with alcohol use disorders. AIDS Behav. 2008;12(1):95–103.PubMedGoogle Scholar
  38. 38.
    Harlow LL, Rose JS, Morokoff PJ, et al. Women HIV sexual risk takers: related behaviors, interpersonal issues, and attitudes. Womens Health. 1998;4(4):407–39.PubMedGoogle Scholar
  39. 39.
    Reback CJ, Lombardi EL. HIV risk behaviors of male-to-female transgenders in a community-based harm reduction program. Int J Transgenderism. 1999;3(1/2):1.Google Scholar
  40. 40.
    Clements K, Kitano K, Wilkinson W, Marx R. HIV Prevention and health service needs of the transgender community in San Francisco. Int J Transgenderism. 1999 Jan;3(1/2):2–17.Google Scholar
  41. 41.
    Parsons JT, Grov C, Kelly BC. Comparing the effectiveness of two forms of time-space sampling to identify club drug-using young adults. J Drug Issues. 2008;38(4):1061–81.PubMedGoogle Scholar
  42. 42.
    Halkitis PN, Pollock JA, Pappas MK, et al. Substance use in the MSM population of New York City during the era of HIV/AIDS. Subst Use Misuse. 2011;46(2–3):264–73.PubMedGoogle Scholar
  43. 43.
    Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis. Am J Prev Med. 2013;44(1):S91–8.PubMedGoogle Scholar
  44. 44.
    Blashill AJ, Perry N, Safren SA. Mental health: a focus on stress, coping, and mental illness as it relates to treatment retention, adherence, and other health outcomes. Curr HIV/AIDS Rep. 2011;8(4):215–22.PubMedGoogle Scholar
  45. 45.
    Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.PubMedGoogle Scholar
  46. 46.
    Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.PubMedGoogle Scholar
  47. 47.
    Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr. 2010;53(2):266–72.PubMedGoogle Scholar
  48. 48.
    Rabkin JG. HIV and depression: 2008 review and update. Curr HIV/AIDS Rep. 2008;5(4):163–71.PubMedGoogle Scholar
  49. 49.
    Gonzalez JS, Psaros C, Batchelder A, Applebaum A, Newville H, Safren SA. Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. Ann Behav Med. 2011;42(1):120–6.PubMedGoogle Scholar
  50. 50.
    Safren SA, Blashill AJ, Lerner J, et al. Higher levels of psychosocial syndemics associated with non-adherence in individuals with HIV screening for a depression treatment trial. Presentation submitted to the 8th International Conference on HIV Treatment and Prevention Adherence; 2013 Jun 2–4; Miami, FL.Google Scholar
  51. 51.
    Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.PubMedGoogle Scholar
  52. 52.
    Berg CJ, Michelson SE, Safren SA. Behavioral aspects of HIV care: adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin North Am. 2007;21(1):181–200.PubMedGoogle Scholar
  53. 53.
    Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic. Syndr. 2006;43(4):411–7.PubMedGoogle Scholar
  54. 54.
    Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775–85.PubMedGoogle Scholar
  55. 55.
    Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108.PubMedGoogle Scholar
  56. 56.
    French T, Tesoriero J, Agins B. Changes in stress, substance use and medication beliefs are associated with changes in adherence to HIV antiretroviral therapy. AIDS Behav. 2011;15(7):1416–28.PubMedGoogle Scholar
  57. 57.
    Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA. Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav. 2013;17(1):168–73.PubMedGoogle Scholar
  58. 58.
    Lehavot K, Huh D, Walters KL, King KM, Andrasik MP, Simoni JM. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence. AIDS Patient Care STDS. 2011;25(3):181–9.PubMedGoogle Scholar
  59. 59.
    Lillie-Blanton M, Stone VE, Snow Jones A, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health. 2010;100(8):1493–9.PubMedGoogle Scholar
  60. 60.
    Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Commun Health. 2004;29(2):117–27.Google Scholar
  61. 61.
    Friedman MS, Marshal MP, Stall R, et al. Associations between substance use, sexual risk taking and HIV treatment adherence among homeless people living with HIV. AIDS Care. 2009;21(6):692–700.PubMedGoogle Scholar
  62. 62.
    Royal SW, Kidder DP, Patrabansh S, et al. Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV. AIDS Care. 2009;21(4):448–55.PubMedGoogle Scholar
  63. 63.
    Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003;80(3):416–27.PubMedGoogle Scholar
  64. 64.
    Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817–33.PubMedGoogle Scholar
  65. 65.
    Gonzalez A, Barinas J, O’Cleirigh C. Substance use: impact on adherence and HIV medical treatment. Curr HIV/AIDS Rep. 2011;8(4):223–34.PubMedGoogle Scholar
  66. 66.
    Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490–8.PubMedGoogle Scholar
  67. 67.
    Haberer JE, Baeten JM, Celum CL, et al. Near perfect early adherence to antiretroviral pre-exposure prophylaxis (PrEP) against HIV infection among HIV-serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP Study. Presented at the 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27–Mar 2; Boston, MA.Google Scholar
  68. 68.
    Haberer JE, Baeten JM, Campbell J, et al. High efficacy and high adherence with pre-exposure prophylaxis (PrEP) for HIV prevention: a prospective study of HIV serodiscordant couples in East Africa (under review).Google Scholar
  69. 69.
    Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7(4):201–9.PubMedGoogle Scholar
  70. 70.
    Dearing JW, Smith DK, Larson RS, Estabrooks CA. Designing for diffusion of a biomedical intervention. Am J Prev Med. 2013;44(1 Suppl 2):S70–6.PubMedGoogle Scholar
  71. 71.
    Malotte CK. Brief risk-reduction counseling in clinical settings for HIV pre-exposure prophylaxis. Am J Prev Med. 2013;44(1 Suppl 2):S112–8.PubMedGoogle Scholar
  72. 72.
    Smith DK, Dearing JW, Sanchez T, Goldschmidt RH. Introducing wicked issues for HIV pre-exposure prophylaxis implementation in the U.S. Am J Prev Med. 2013;44(1 Suppl 2):S59–62.PubMedGoogle Scholar
  73. 73.
    Thrun MW. Provider-initiated HIV-risk behavior counseling in the context of HIV pre-exposure prophylaxis. Am J Prev Med. 2013;44(1 Suppl 2):S108–11.PubMedGoogle Scholar
  74. 74.
    Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46–55.PubMedGoogle Scholar
  75. 75.
    Zhou F, Gao L, Li S, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One. 2012;7(3):e32329.PubMedGoogle Scholar
  76. 76.
    Lee RS, Kochman A, Sikkema KJ. Internalized stigma among people living with HIV-AIDS. AIDS Behav. 2002;6(4):309–19.Google Scholar
  77. 77.
    Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS. 2006;20(5):359–68.PubMedGoogle Scholar
  78. 78.
    Wolitski RJ, Pals SL, Kidder DP, Courtenay-Quirk C, Holtgrave DR. The effects of HIV stigma on health, disclosure of HIV status, and risk behavior of homeless and unstably housed persons living with HIV. AIDS Behav. 2009;13(6):1222–32.PubMedGoogle Scholar
  79. 79.
    Earnshaw VA, Chaudoir SR. From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures. AIDS Behav. 2009;13(6):1160–77.PubMedGoogle Scholar
  80. 80.
    Starks TJ, Rendina HJ, Breslow AS, Parsons JT, Golub SA. The psychological cost of anticipating HIV stigma for HIV-negative gay and bisexual men. AIDS Behav. 2013: 1–10 (Epub 2013).Google Scholar
  81. 81.
    Galvan FH, Davis EM, Banks D, Bing EG. HIV stigma and social support among African Americans. AIDS Patient Care STDS. 2008;22(5):423–36.PubMedGoogle Scholar
  82. 82.
    Prachakul W, Grant JS, Keltner NL. Relationships among functional social support, HIV-related stigma, social problem solving, and depressive symptoms in people living with HIV: a pilot study. J Assoc Nurse AIDS Care. 2007;18(6):67–76.Google Scholar
  83. 83.
    Wohl AR, Galvan FH, Myers HF, et al. Do social support, stress, disclosure and stigma influence retention in HIV care for Latino and African American men who have sex with men and women? AIDS Behav. 2011;15(6):1098–110.PubMedGoogle Scholar
  84. 84.
    Kingori C, Reece M, Obeng S, et al. Impact of internalized stigma on HIV prevention behaviors among HIV-infected individuals seeking HIV care in Kenya. AIDS Patient Care STDS. 2012;26(12):761–8.PubMedGoogle Scholar
  85. 85.
    Steward WT, Bharat S, Ramakrishna J, Heylen E, Ekstrand ML. Stigma is associated with delays in seeking care among HIV-infected people in India. J Int Assoc Provid AIDS Care. 2013;12(2):103–9.Google Scholar
  86. 86.
    Vanable PA, Carey MP, Blair DC, Littlewood RA. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav. 2006;10(5):473–82.PubMedGoogle Scholar
  87. 87.
    Chesney MA, Smith AW. Critical delays in HIV testing and care. Am Behav Sci. 1999;42(7):1162–74.Google Scholar
  88. 88.
    Mahajan AP, Sayles JN, Patel VA, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22(Suppl 2):S67–79.PubMedGoogle Scholar
  89. 89.
    Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408–21.PubMedGoogle Scholar
  90. 90.
    Tangmunkongvorakul A, Chariyalertsak S, Amico KR, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care (Epub 2012).Google Scholar
  91. 91.
    Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25(2):63–71.PubMedGoogle Scholar
  92. 92.
    Johnson MO, Carrico AW, Chesney MA, Morin SF. Internalized heterosexism among HIV-positive, gay-identified men: implications for HIV prevention and care. J Consult Clin Psychol. 2008;76(5):829–39.PubMedGoogle Scholar
  93. 93.
    Preston DB, D’Augelli AR, Kassab CD, Cain RE, Schulze FW, Starks MT. The influence of stigma on the sexual risk behavior of rural men who have sex with men. AIDS Educ Prev. 2004;16(4):291–303.PubMedGoogle Scholar
  94. 94.
    Wohl AR, Galvan FH, Carlos J-A, et al. A comparison of MSM stigma, HIV stigma and depression in HIV-positive Latino and African American men who have sex with men (MSM). AIDS Behav (Epub 2012).Google Scholar
  95. 95.
    Przybyla SM, Golin CE, Widman L, Grodensky CA, Earp JA, Suchindran C. Serostatus disclosure to sexual partners among people living with HIV: examining the roles of partner characteristics and stigma. AIDS Care (Epub 2012).Google Scholar
  96. 96.
    Ware NC, Wyatt MA, Haberer JE, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463–8.PubMedGoogle Scholar
  97. 97.
    Hogben M, Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis. 2008;35(12):1009–10.PubMedGoogle Scholar
  98. 98.
    Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007;370(9581):89–93.PubMedGoogle Scholar
  99. 99.
    Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health. 2011;101(6):982–5.PubMedGoogle Scholar
  100. 100.
    Supervie V, García-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A. 2010;107(27):12381–6.PubMedGoogle Scholar
  101. 101.
    Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.PubMedGoogle Scholar
  102. 102.
    Mustanski BS, Newcomb ME, Du Bois SN, Garcia SC, Grov C. HIV in young men who have sex with men: a review of epidemiology, risk and protective factors, and interventions. J Sex Res. 2011;48(2–3):218–53.PubMedGoogle Scholar
  103. 103.
    Beidas RS, Birkett M, Newcomb ME, Mustanski B. Do psychiatric disorders moderate the relationship between psychological distress and sexual risk-taking behaviors in young men who have sex with men? A longitudinal perspective. AIDS Patient Care STDS. 2012;26(6):366–74.PubMedGoogle Scholar
  104. 104.
    Sikkema KJ, Hansen NB, Meade CS, Kochman A, Fox AM. Psychosocial predictors of sexual HIV transmission risk behavior among HIV-positive adults with a sexual abuse history in childhood. Arch Sex Behav. 2009;38(1):121–34.PubMedGoogle Scholar
  105. 105.
    Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35(2):389–416.PubMedGoogle Scholar
  106. 106.
    Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000;23(5):396–404.PubMedGoogle Scholar
  107. 107.
    Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.PubMedGoogle Scholar
  108. 108.
    Mellins CA, Havens JF, McDonnell C, et al. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009;21(2):168–77.PubMedGoogle Scholar
  109. 109.
    Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2):94–103.PubMedGoogle Scholar
  110. 110.
    Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA. 2006;296(7):863–5.PubMedGoogle Scholar
  111. 111.
    Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedGoogle Scholar
  112. 112.
    Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 2000;287(5453):650–4.PubMedGoogle Scholar
  113. 113.
    Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Proceedings of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 2011 Jul 17–20; Rome, Italy. p. 17–20.Google Scholar
  114. 114.
    Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002–8.PubMedGoogle Scholar
  115. 115.
    Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir Ther. 2000;5(1):19–22.PubMedGoogle Scholar
  116. 116.
    Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352(9142):1751–2.PubMedGoogle Scholar
  117. 117.
    Krakower D, Mayer KH. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep. 2011;8(4):241–8.PubMedGoogle Scholar
  118. 118.
    Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997–1005.PubMedGoogle Scholar
  119. 119.
    González-Guarda RM, Florom-Smith AL, Thomas T. A syndemic model of substance abuse, intimate partner violence, HIV infection, and mental health among Hispanics. Public Health Nurs. 2011;28(4):366–78.PubMedGoogle Scholar
  120. 120.
    Collins PY, Geller PA, Miller S, Toro P, Susser ES. Ourselves, our bodies. our realities: an HIV prevention intervention for women with severe mental illness. J Urban Health. 2001;78(1):162–75.PubMedGoogle Scholar
  121. 121.
    Collins PY, Von Unger H, Putnins S, Crawford N, Dutt R, Hoffer M. Adding the female condom to HIV prevention interventions for women with severe mental illness: a pilot test. Community Ment Health J. 2011;47(2):143–55.PubMedGoogle Scholar
  122. 122.
    Seth P, Patel SN, Sales JM, DiClemente RJ, Wingood GM, Rose ES. The impact of depressive symptomatology on risky sexual behavior and sexual communication among African American female adolescents. Psychol Health Med. 2011;16(3):346–56.PubMedGoogle Scholar
  123. 123.
    Cavanaugh CE, Hansen NB, Sullivan TP. HIV sexual risk behavior among low-income women experiencing intimate partner violence: the role of posttraumatic stress disorder. AIDS Behav. 2010;14(2):318–27.PubMedGoogle Scholar
  124. 124.
    Stockman JK, Ludwig-Barron N, Hoffman MA, Ulibarri MD, Dyer TVP. Prevention interventions for human immunodeficiency virus in drug-using women with a history of partner violence. Subst Abuse Rehabil. 2012;2012(3):45–57.Google Scholar
  125. 125.
    Kippax S, Stephenson N. Beyond the distinction between biomedical and social dimensions of HIV prevention through the lens of a social public health. Am J Public Health. 2012;102(5):789–99.PubMedGoogle Scholar
  126. 126.
    Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: results from the Steps Study. AIDS Behav. 2011;15(6):1161–70.PubMedGoogle Scholar
  127. 127.
    Freeman M, Patel V, Collins PY, Bertolote J. Integrating mental health in global initiatives for HIV/AIDS. Br J Psychiatry. 2005;187:1–3.PubMedGoogle Scholar
  128. 128.
    Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5(4):186–92.PubMedGoogle Scholar
  129. 129.
    McGowan I. Rectal microbicides: can we make them and will people use them? AIDS Behav. 2011;15(Suppl 1):S66–71.PubMedGoogle Scholar
  130. 130.
    Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis. 2012;12:289.PubMedGoogle Scholar
  131. 131.
    Mansergh G, Marks G, Rader M, Colfax GN, Buchbinder S. Rectal use of nonoxynol-9 among men who have sex with men. AIDS. 2003;17(6):905–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Aaron J. Blashill
    • 1
    • 2
    • 3
    Email author
  • Jonathan Lassiter
    • 4
  • Johannes M. Wilson
    • 1
  • Steven A. Safren
    • 1
  • Jeffrey T. Parsons
    • 5
  1. 1.Massachusetts General HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.The Fenway InstituteBostonUSA
  4. 4.Center for HIV/AIDS Educational Studies and Training (CHEST)New YorkUSA
  5. 5.Hunter College and the Graduate Center of the City University of New York (CUNY)New YorkUSA

Personalised recommendations